Vertebral Artery Dissection in a Migraine Patient Treated with CGRP Monoclonal Antibody
Author Information
Author(s): Tokuyasu Daiki, Imai Shungo, Chen Shih-Pin, Ihara Keiko, Watanabe Narumi, Izawa Yoshikane, Nakahara Jin, Hori Satoko, Takizawa Tsubasa
Primary Institution: Keio University School of Medicine
Conclusion
The use of CGRP monoclonal antibodies may be related to cervical artery dissection and requires further investigation.
Supporting Evidence
- Migraine is associated with cervical artery dissection.
- CGRP is a neuropeptide that may affect cerebrovascular disease risk.
- The FAERS database showed elevated reporting odds ratios for galcanezumab and CGRP mAbs.
Takeaway
A woman with migraine developed a serious neck problem after taking a migraine medication, and this needs more study to understand the risks.
Methodology
The study involved a case report and analysis of the FDA Adverse Event Reporting System (FAERS) database.
Potential Biases
The FAERS database is a voluntary reporting system, which may lead to underreporting or overreporting of adverse events.
Limitations
The association between the medication and the dissection is unclear, and the FAERS database may include reporting biases.
Participant Demographics
A 39-year-old woman with no vascular risk factors.
Statistical Information
Confidence Interval
95% CI: 6.22–31.4 for galcanezumab; 95% CI: 3.75–13.3 for CGRP mAbs.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website